MedPath

Retlirafusp alfa

Generic Name
Retlirafusp alfa
Drug Type
Biotech
CAS Number
2395839-91-3
Unique Ingredient Identifier
JP6N6TA92L
Clinical Trials
Related News

Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma

Not Applicable
Not yet recruiting
Conditions
Hepatocellular Carcinoma(HCC)
Interventions
Drug: FOLFOX4
Procedure: HAIC
Procedure: Local treatment
Drug: The original treatment regimen
First Posted Date
2025-03-25
Last Posted Date
2025-03-25
Lead Sponsor
Nanjing Tianyinshan Hospital
Target Recruit Count
300
Registration Number
NCT06893887

Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping

Phase 2
Not yet recruiting
Conditions
Gastric Cancer
HER2 + Gastric Cancer
PD-L1 Positive
CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction
Interventions
First Posted Date
2025-03-18
Last Posted Date
2025-03-18
Lead Sponsor
China Medical University, China
Target Recruit Count
140
Registration Number
NCT06881017

SHR-1701 Combined with SHR2554 and BP102 for MCRC

Phase 2
Not yet recruiting
Conditions
Colorectal Cancer Metastatic
Interventions
First Posted Date
2024-11-07
Last Posted Date
2024-11-07
Lead Sponsor
Fudan University
Target Recruit Count
20
Registration Number
NCT06679673
Locations
🇨🇳

Department of Colorectal Surgery Fudan University Shanghai Caner Center, Shanghai, Shanghai, China

SHR1701 Alone or in Combination With SHR2554 in Relapsed or Refractory Classical Hodgkin Lymphoma

Phase 1
Recruiting
Conditions
Relapsed or Refractory Hodgkin Lymphoma
Interventions
Drug: SHR2554+ SHR1701
First Posted Date
2023-06-09
Last Posted Date
2023-06-15
Lead Sponsor
Chinese PLA General Hospital
Target Recruit Count
100
Registration Number
NCT05896046
Locations
🇨🇳

Han wei dong, Beijing, Beijing, China

SHR-1701 for Consolidation Therapy After Concurrent Chemoradiotherapy in Inoperable Stage III NSCLC

Phase 2
Not yet recruiting
Conditions
NSCLC, Stage III
Interventions
First Posted Date
2022-01-04
Last Posted Date
2022-01-04
Lead Sponsor
Shanghai Chest Hospital
Target Recruit Count
19
Registration Number
NCT05177497

To Explore the Efficacy and Safety of SHR-1701 Combined With Temozolomide in the Treatment of Advanced Melanoma

Phase 2
Recruiting
Conditions
Melanoma
Interventions
First Posted Date
2021-11-03
Last Posted Date
2023-06-07
Lead Sponsor
Yong Chen
Target Recruit Count
31
Registration Number
NCT05106023
Locations
🇨🇳

Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

SHR-1701 in Combination With Famitinib in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

Phase 1
Conditions
Nasopharyngeal Carcinoma
Interventions
First Posted Date
2021-08-25
Last Posted Date
2021-08-25
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Target Recruit Count
30
Registration Number
NCT05020925
Locations
🇨🇳

Cancer Hospital of Guangzhou Sun Yat-sen University, Guangzhou, Guangdong, China

A Trial of SHR-1701 in Combination With and Without Famitinib Malate in Patients With Extensive Stage Small Cell Lung Cancer

Phase 2
Conditions
Lung Cancer
Interventions
First Posted Date
2021-05-12
Last Posted Date
2021-05-12
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Target Recruit Count
106
Registration Number
NCT04884009

A Trial of SHR-1701 With or Without Famitinib in Patients With Advanced or Metastatic NSCLC

Phase 2
Withdrawn
Conditions
Non-Small-Cell Lung Cancer
Interventions
Drug: SHR-1701，Famitinib
First Posted Date
2021-01-07
Last Posted Date
2023-06-07
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Registration Number
NCT04699968

SHR-1701 in Patients With Recurrent/Metastatic Scchn

Phase 2
Conditions
Squamous Cell Carcinoma of Head and Neck
Interventions
First Posted Date
2020-12-02
Last Posted Date
2021-10-29
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Target Recruit Count
130
Registration Number
NCT04650633
Locations
🇨🇳

Tumor Hospital of the Chinese Academy of Medical Sciences, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy